Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus

• Published in: Gynecologic oncology Vol. 110; no. 2; pp. 196 - 201
• Main Authors: Moore, Richard G., Brown, Amy K., Miller, M. Craig, Badgwell, Donna, Lu, Zhen, Allard, W. Jeffrey, Granai, C.O., Bast, Robert C., Lu, Karen
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.08.2008
• Subjects: Adenocarcinoma - blood; Adenocarcinoma - pathology; Adult; Aged; Aged, 80 and over; Antigens, Tumor-Associated, Carbohydrate - blood; beta-Defensins; Biomarkers, Tumor - blood; CA-125 Antigen - blood; Endometrial cancer; Endometrial Neoplasms - blood; Endometrial Neoplasms - pathology; Epididymal Secretory Proteins - metabolism; Female; GPI-Linked Proteins; HE4; Hematology, Oncology and Palliative Medicine; Humans; Membrane Glycoproteins - blood; Middle Aged; Neoplasm Staging; Obstetrics and Gynecology; Sensitivity and Specificity; Tumor marker; Tumor marker; Endometrial cancer; HE4

Tumor markers with increased sensitivity and specificity for endometrial cancer are needed to help monitor response to therapy and to detect recurrent disease. Currently, the tumor maker CA125 is utilized in this role with limited value. The objectives of this study were to examine the levels of sev...